Resetting After Your Lead Drug Fails
Santhera CEO On Transparency In The Face Of Adversity
Executive Summary
Becoming a first-time CEO of a biotech company in 2020 meant dealing with unexpected challenges without any instruction book to follow. Santhera Pharmaceuticals’ Dario Eklund not only had COVID-19 upheaval to manage, but also a late-stage trial failure, a virtual financing and a new plan for the company to sell to stakeholders.
You may also be interested in...
Santhera Pulls EU Filing For Failed DMD Candidate
Swiss company Santhera's lengthy and problem-laden journey to repurpose its already marketed idebenone for use in Duchenne Muscular Dystrophy has ended in failure. The company has withdrawn its EU filing for the product following its announcement that it was halting development.
Rising From The Ashes Of 2020: ‘We Must Not Waste The Learning,’ Says Dame Sally
UK special envoy on antimicrobial resistance Professor Dame Sally Davies, who is also the former chief medical officer for England, talks to In Vivo about the challenges of 2020, the importance of a strong working relationship between the public and private sectors, and reaching a turning point on AMR.
In Vivo’s Deals Of The Year 2020: Cast Your Vote!
It is time for In Vivo's 13th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Need a specific report? 1000+ reports available
Buy Reports